Business
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy Myositis seamless adaptive clinical trial design provides potential opportunity for a si
About this update from Cartesian Therapeutics, Inc.
[{"type":"image","alt":"Cartesian Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cartesian Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/d8abef5500410e9a7353f02873aa8d43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vlOyY4EEsvNCPN1.1VEVug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d8abef5500410e9a7353f02873aa8d43","width":300,"height":75}},"lazy":false},{"type":"text","content":"100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ","length":141,"tagName":"p"},{"type":"text","content":"Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3)","length":105,"tagName":"p"},{"type":"text","content":"Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy","length":163,"tagName":"p"},{"type":"text","content":"Myositis seamless adaptive clinical trial design provides potential opportunity for a single pivotal trial expected to commence in 1H26","length":135,"tagName":"p"},{"type":"text","content":"FREDERICK, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus (SLE). Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T).","length":507,"tagName":"p"},{"type":"text","content":"“The responses observed in all participants reaching Month 3 follow-up to date in the ongoing Phase 2 SLE trial serves as strong validation for our proprietary platform technology and supports the potential of Descartes-08 to expand the reach of cell therapy for the treatment of autoimmune diseases,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “Consistent with clinical data reported to date from our myasthenia gravis program, Descartes-08 was well-...